HORIZON PHARMACEUTICALS LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2020

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2020

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3 to 4

HORIZON PHARMACEUTICALS LIMITED

COMPANY INFORMATION FOR THE YEAR ENDED 30 APRIL 2020

DIRECTORS: A Pandya

Dr D Pandya

REGISTERED OFFICE: Ross House

The Square Stow on the Wold Cheltenham Gloucestershire GL54 1AF

REGISTERED NUMBER: 07484452 (England and Wales)

ACCOUNTANTS: William Hinton Limited

Chartered Accountants Ross House

The Square Stow On The Wold Gloucestershire GL54 1AF

BALANCE SHEET 30 APRIL 2020

		2020		2019	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible assets	4		675		1,013
CURRENT ASSETS					
Debtors	5	11,902		1,350	
Cash at bank		60,343_		101,285	
		72,245		102,635	
CREDITORS					
Amounts falling due within one year	6	2,431		3,924	
NET CURRENT ASSETS			69,814		98,711
TOTAL ASSETS LESS CURRENT					
LIABILITIES			<u>70,489</u>		99,724
CAPITAL AND RESERVES					
Called up share capital			160,000		160,000
Retained earnings			(89,511)		(60,276)
SHAREHOLDERS' FUNDS			70,489		99,724

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2020 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the
- (b) end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 July 2020 and were signed on its behalf by:

A Pandya - Director

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2020

1. STATUTORY INFORMATION

Horizon Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Plant and machinery etc - 25% per annum on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2019 - 3).

-3- continued...

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2020

4.	TANGIBLE FIXED ASSETS		
			Plant and
			machinery
			etc
	COST		£
	At I May 2019		
	and 30 April 2020		1,350
	DEPRECIATION		
	At 1 May 2019		337
	Charge for year		338
	At 30 April 2020		675
	NET BOOK VALUE		
	At 30 April 2020		<u>675</u>
	At 30 April 2019		
5.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2020	2019
		£	£
	Trade debtors	8,802	1,350
	Other debtors	3,100	
		<u>11,902</u>	1,350
6.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2020	2019
		£	£
	Trade creditors	96	292
	Taxation and social security	-	1,298
	Other creditors	2,335	2,334
		<u>2,431</u>	<u>3,924</u>

7. ULTIMATE CONTROLLING PARTY

The controlling party is A Pandya.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.